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Abstract 
 
Glioblastoma Multiforme (GBM), the most common primary brain tumor in adult patients, is a 
grade IV astrocytic neoplasm characterized histologically by high mitotic index, significant 
angiogenesis, necrosis, and local invasion.  This infiltrative nature leads to inevitable tumor 
recurrence even after conventional radiation and chemotherapeutic treatment.  With a median 
patient survival of less than one year, there is a great need for a better understanding of the 
molecular basis of these malignant behaviors in order to develop effective molecular based 
therapies.   
We have been investigating the role played by the bioactive lipid sphingosine-1-
phosphate (S1P) in GBM.  S1P stimulates growth, motility, invasiveness, angiogenesis, and 
adhesion in a variety of tumor cell types.  We have previously shown that S1P stimulates growth 
and invasion of glioma cells through its receptors (S1P1-3) which are commonly expressed in 
GBM tissue.  In addition, we have also shown that high levels of the enzyme responsible for S1P 
production, sphingosine kinase (SphK), correlate with *poorer survival of GBM patients.  This 
study uses receptor manipulated GBM cell lines to delineate the contributions of the various S1P 
receptors to the malignant behavior of well established GBM cell lines. The results show that 
S1P1 and S1P3 stimulate growth, motility, and invasion.  S1P2 also stimulates GBM cell growth.  
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Although S1P2 decreases GBM cell motility, surprisingly it increases invasion, by enhancing 
attachment to extracellular matrix material.  This unusual enhancement of invasion by S1P2 also 
required upregulation of the matricellular protein CCN1/Cyr61, since this effect was blocked by 
neutralizing antibodies against this effector molecule.   
Furthermore, we have begun to investigate the role of S1P in both normal neural stem 
cells and brain tumor stem cells (BTSC) derived from GBM tissue.  BTSC are a subpopulation 
of cells present in GBM which, unlike traditional GBM cell lines, form tumors in animal models 
that resemble GBMs histologically and invade into surrounding brain tissue.  BTSC are likely 
the formative cells of GBM tumors and may be derived from the transformation of normal neural 
stem cells.  Spheroid invasion assays show that S1P stimulates invasion of both BTSC and neural 
stem cells, while SphK inhibitors block the invasion of BTSC.  These data suggest that these 
cells are highly responsive to S1P and that enhanced SphK in GBM BTSC could drive the 
invasion of these cells.  In summary, our data identify downstream mediators of S1P in GBM 
cells that may mediate enhanced malignant behavior of these tumors.  Several of these mediators 
may be useful as therapeutic targets.  In addition, our data implicate S1P and SphK in the 
invasiveness of the crucial BTSC.  
 
Introduction 
 
Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates cellular proliferation, 
migration, survival, cytoskeletal rearrangement, and angiogenesis (Spiegel and Milstien 2003; 
Hla 2004; Young and Van Brocklyn 2006).  With the discovery of the S1P family of receptors 
throughout the 1990’s, autocrine/paracrine receptor stimulation influence on cellular activity has 
been under intense investigation.    S1P signals both intracellularly as a second messenger 
(Spiegel and Milstien 2003) and through five cell surface, G protein-coupled receptors (GPCRs)  
S1P1-5 (Young and Van Brocklyn 2006).  Knock out models in mice have shown the critical 
individual receptor subtype importance in establishing a normal phenotype (Ishii, Ye et al. 2002).  
Before identification of receptors, sphingosine kinase (SK) production of S1P was thought to 
solely be responsible for modulating the intracellular effects of this lipid. Presently, the specific 
signaling pathways of both intracellular S1P as well as extracellular receptor stimulation remain 
to be conclusively elucidated.   
Our group has been exploring the roles played by S1P in the growth and invasiveness of 
glioblastoma multiforme (GBM) cells.  GBM is the most commonly occurring primary brain 
tumor in adults and is highly malignant, displaying aggressive growth and invasion into 
surrounding brain tissue (Lefranc, Sadeghi et al. 2006) leading to a median life expectancy of 
only 10-12 months following diagnosis (Sathornsumetee and Rich 2006).  A better 
understanding of the molecular regulation of GBM cell growth and invasion will be necessary to 
develop effective molecular-based therapies. 
Upon S1P receptor stimulation, G-protein pathways lead to distinct cellular effects that 
have been observed and characterized both in vitro and in vivo.  We have shown that S1P is 
mitogenic for (Van Brocklyn, Letterle et al. 2002), and enhances motility and invasiveness of 
GBM cell lines (Van Brocklyn, Young et al. 2003).  As an indication of the importance of this 
signaling system for in vivo GBM, high expression levels of the enzyme which forms S1P, 
sphingosine kinase-1 (SphK1), in GBM tissue correlate with a more than 3 fold shorter survival 
time of GBM patients (Figure 1) (Van Brocklyn, Jackson et al. 2005).  Furthermore, knockdown 
of SphK1 or SphK2 expression using RNA interference decreases GBM cell proliferation by 
preventing entry of cells in the cell cycle (Van Brocklyn, Jackson et al. 2005).  
The mitogenic and invasive effects of S1P on GBM cells are at least partially mediated 
through its GPCRs, since both responses are sensitive to pertussis toxin (Van Brocklyn, Letterle 
et al. 2002), which specifically inhibits signaling through the Gi/o family of G proteins.  
Moreover, S1P induction of both mitogenesis and invasiveness of GBM cells occurs at 
nanomolar concentrations, consistent with the affinities of S1P for its receptors (Van Brocklyn, 
Letterle et al. 2002).  GBM cell lines (Van Brocklyn, Young et al. 2003) and GBM tissue (Van 
Brocklyn, Jackson et al. 2005) commonly express three S1P receptors, S1P1, S1P2 and S1P3.  
S1P4, which is primarily expressed in cells of hematopoietic origin (Gräler, Bernhardt et al. 
1998), has not been detected in gliomas.  S1P5 is expressed in normal brain in oligodendrocytes 
(Jaillard, Harrison et al. 2005), however we have detected only very low levels of S1P5 
expression in a limited number of GBM cases and several glioma cell lines (unpublished 
observation).  Unfortunately, a suitable in vivo model of GBM progression employing traditional 
cell lines is not available.  Here, we establish a relevant model to use in nude mice through the 
use of the GBM cell line X-12, which is passaged in the flanks of nude mice rather than in 
culture using traditional in vitro methods.  This cell line is thought contain an enriched 
population of transformed neural stem cells that serve as the formative brain tumor stem cells 
(BTSC) in GBM tumors.  We were able to histopathologically recapitulate the local invasiveness 
characteristically observed in human GBM cases through intracranial injections into nude mice 
(Figure 2).   
Each S1P receptor subtype activates a unique set of G proteins with varying preferences 
(Taha, Argraves et al. 2004; Young and Van Brocklyn 2006).  Therefore, the individual 
influence of each receptor subtype on S1P regulation of GBM cell behavior may depend on the 
amounts of the individual S1P receptors expressed.  
Results and Discussion 
In this study, the effects of S1P through individual receptor subtypes on glioma cell 
growth, migration, invasion, and adhesion were examined by overexpressing individual S1P 
receptors in glioma cells with low endogenous receptor levels, and knocking down individual 
S1P receptor expression by RNA interference in glioma cells with high levels of expression 
(Table 1).  The results show that S1P1, S1P2 and S1P3 all contribute to glioma cell growth (Figure 
3) and invasion (Figure 4) through distinct, but overlapping, mechanisms.  Conversely, S1P5 
inhibits these cellular activities when overexpressed in glioma cells (Figures 3-5).  Furthermore, 
the S1P2 receptor subtype displays a novel enhancement of S1P-stimulated invasion while 
decreasing migration (Figure 4).  The S1P2-stimulated invasiveness in these glioma cell lines 
correlates with enhanced cell adhesion (Figure 5) and is mediated, at least partially, by the 
matricellular protein CCN1/Cyr61 (Figure 6).  Additionally, the S1P2 mediated response was 
also shown in a spheroid invasion assay (Figure 7), which serves as a more relevant model to 
gauge in vivo tumor invasiveness (Bauman, Fisher et al. 1999).  This differential influence of the 
same ligand is therefore dependent on the receptor subtype expressed by the cell.  Since each 
S1P receptor subtype signals through a unique set of G-proteins that result in various 
downstream cellular effects, it is then critical to know what receptors are present in order to 
predict cellular behavior with ligand stimulation. 
The X-12 GBM cell line was then examined to identify S1P induced effects on 
invasiveness.  Since these cells are thought to potentially arise from neural stem cell 
transformation, we also used the neural stem cell line SFME to compare in a spheroid invasion 
assay.  S1P clearly induced invasiveness in neural stem cells and we interestingly found that 
treatment with S1P promoted additional extracellular matrix infiltration above that observed at 
endogenous levels in X-12 GBM cells (Figure 8).  Furthermore, Sphk inhibitor effectively 
reduced this endogenous response (Figure 9).  We therefore conclude that the X-12 GBM cell 
line resembles neural stem cells in S1P induced invasiveness and that Sphk expression plays a 
key role in the endogenous X-12 invasion response. 
 With such dramatic cellular effects influencing these GPCRs individually with 
S1P presence, understanding the role of activation of each subtype can have great medical 
impact.  In 2001, 50% of current commercially available pharmaceuticals targeted GPCRs and 
were a $30 billion dollar industry (Klabunde and Hessler 2002). In addition, these 
pharmaceuticals represented approximately one quarter of the top 100 selling drugs.  
Furthermore, biological influence of these mechanisms is apparent considering that S1P 
receptors are present in virtually every tissue and cell type and S1P blood levels range from 0.1-
1μM, which is greater than the Kd of each receptor (Goetzl and Rosen 2004).  Also, SphK1 
overexpression has been correlated to several other forms of cancer, including breast, lung, and 
colon tumors when compared to normal tissue (French, Schrecengost et al. 2003).  Although 
some functional redundancy is evident, the extent of preferential G protein pathway activation 
has yet to be examined and characterized in detail for each individual receptor subtype.  With 
this understanding, opportune clinical application in the molecular based therapeutic treatment of 
a variety of cancers will be possible.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8. SFME or X-12 cells were grown as neurospheres in defined media suspension before being transplanted into a Matrigel 
matrix without and with 100nm S1P in serum free media.  Spheroid invasion was observed through 10x photographs taken at the 
indicated time points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References: 
 
 
Bauman, G. S., B. J. Fisher, et al. (1999). "Effects of radiation on a three-dimensional model of 
malignant glioma invasion." Int. J. Dev. Neurosci. 17(5-6): 643-651. 
French, K. J., R. S. Schrecengost, et al. (2003). "Discovery and evaluation of inhibitors of human 
sphingosine kinase." Cancer Res. 63(18): 5962-2969. 
Goetzl, E. J. and H. Rosen (2004). "Regulation of immunity by lysosphingolipids and their G 
protein-coupled receptors." J. Clin. Invest. 114(11): 1531-1537. 
Gräler, M. H., G. Bernhardt, et al. (1998). "EDG6, a novel G-protein-coupled receptor related to 
receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue." 
Genomics 53(2): 164-169. 
Hla, T. (2004). "Physiological and pathological actions of sphingosine 1-phosphate." Semin. Cell 
Dev. Biol. 15(5): 513-520. 
Ishii, I., X. Ye, et al. (2002). "Marked perinatal lethality and cellular signaling deficits in mice 
null for the two sphingosine 1-phosphate receptors, S1P2/LPB2/EDG-5 and 
S1P3/LPB3/EDG-3." J. Biol. Chem. 277(28): 25152-25159. 
Jaillard, C., S. Harrison, et al. (2005). "Edg8/S1P5: an oligodendroglial receptor with dual 
function on process retraction and cell survival." J. Neurosci. 25(6): 1459-1469. 
Klabunde, T. and G. Hessler (2002). "Drug design strategies for targeting G-protein-coupled 
receptors." Chembiochem 3(10): 928-944. 
Lefranc, F., N. Sadeghi, et al. (2006). "Present and potential future issues in glioblastoma 
treatment." Expert Rev Anticancer Ther 6(5): 719-32. 
Sathornsumetee, S. and J. N. Rich (2006). "New treatment strategies for malignant gliomas." 
Expert Rev Anticancer Ther 6(7): 1087-104. 
Spiegel, S. and S. Milstien (2003). "Exogenous and intracellularly generated sphingosine 1-
phosphate can regulate cellular processes by divergent pathways." Biochem. Soc. Trans. 
31(Pt 6): 1216-1219. 
Spiegel, S. and S. Milstien (2003). "Sphingosine-1-phosphate: an enigmatic signalling lipid." 
Nat. Rev. Mol. Cell Biol. 4(5): 397-407. 
Taha, T. A., K. M. Argraves, et al. (2004). "Sphingosine-1-phosphate receptors: receptor 
specificity versus functional redundancy." Biochim. Biophys. Acta 1682(1-3): 48-55. 
Van Brocklyn, J. R., C. A. Jackson, et al. (2005). "Sphingosine kinase-1 expression correlates 
with poor survival of patients with glioblastoma multiforme.  Roles of sphingosine kinase 
isoforms in growth of glioblastoma cell lines." J. Neuropathol. Exp. Neurol. 64(8): 695-
705. 
Van Brocklyn, J. R., C. A. Letterle, et al. (2002). "Sphingosine-1-phosphate stimulates human 
glioma cell proliferation through Gi-coupled receptors:  Role of ERK MAP kinase and 
phosphatidylinositol 3-kinase β." Cancer Lett. 181(2): 195-204. 
Van Brocklyn, J. R., N. Young, et al. (2003). "Sphingosine-1-phosphate stimulates motility and 
invasiveness of human glioblastoma multiforme cells." Cancer Lett. 199(1): 53-60. 
Young, N. and J. R. Van Brocklyn (2006). "Signal transduction of sphingosine-1-phosphate G 
protein-coupled receptors." ScientificWorldJournal 6: 946-66. 
 
 
